Summary:
- The article discusses the strategic implementation of artificial intelligence within the pharmaceutical industry, specifically focusing on Novartis's transition from experimental AI pilots to large-scale, enterprise-wide integration.
- It highlights the scientific and operational challenges of scaling machine learning, such as data quality, cross-functional collaboration, and the necessity of embedding AI into the core research and development lifecycle to accelerate drug discovery and clinical trials.